Obstetrics/Gynecology
RSSArticles
-
Standard-Dose vs. High-Dose Oxytocin for Labor Augmentation
In this randomized clinical trial of standard-dose vs. high-dose oxytocin regimens for labor augmentation among 1,003 nulliparous women, the primary outcome (cesarean delivery) was similar between the two groups. However, secondary outcomes were lower, labor duration was shorter, and umbilical artery acidemia occurred less frequently.
-
BSO at Benign Hysterectomy: What Should We Be Recommending?
In this population-based retrospective cohort study, among 44,549 adult women undergoing hysterectomy in Ontario, Canada, there was marked variation between surgeons in bilateral salpingo-oophorectomy (BSO) rates after controlling for patient age and other factors. Approximately 41% of patients had no indication for the bilateral salpingo-oophorectomy in their records.
-
Mifepristone as an Adjunct to Misoprostol for Pregnancy Termination
In this prospective, double-blind, randomized, placebo-controlled trial, pretreatment with 200 mg of mifepristone 24 to 48 hours before labor induction using misoprostol significantly reduced time to delivery among demised fetuses between 14 and 28 weeks of gestation. Maternal complications were equivalent in both groups.
-
Changes to Medication Abortion Could Result in Pharmacy Dispensing of the Drug
The easing of the risk evaluation and mitigation strategy restriction on mifepristone will make it easier for women to obtain the drug and could allow for pharmacy dispensing of the drug. Pharmacists should have a seat at the table in the conversation on dispensing prescription medication. -
Researchers Say It Is Time to Drop REMS Restriction on Mifepristone
The risk evaluation and mitigation strategy (REMS) restriction on mifepristone has been burdensome for providers and patients, researchers noted. The REMS restriction exacerbates the stigma around abortion care, which already disproportionately affects communities of color and young people. -
Disease-Specific Contraceptive Counseling Needed for Sickle Cell Disease Patients
Healthcare providers need to focus on educating women with sickle cell disease about different types of contraception, efficacy, and risks while addressing disease-specific concerns. Women with sickle cell disease are at risk for pregnancy complications, such as higher risks for maternal and fetal mortality, pre-eclampsia, and intrauterine growth restriction. -
Researchers Study COVID-19 Vaccine Outreach to Pregnant Women
The results of a recent study highlight the gaps in COVID-19 vaccination among pregnant women in the United States. Although pregnant women are at increased risk for severe illness and death from the disease, many remain unvaccinated. -
Reproductive Health Organizations Help Vaccinate Patients, Communities
Planned Parenthood and other reproductive health organizations have initiated COVID-19 vaccine outreach for their patients and communities. In addition to encouraging staff and patients to take the vaccine, the organizations have taken a positive COVID-19 vaccine message to minority communities and others hit hard by the pandemic. -
Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program
In this cohort study, results from two years of an inpatient postpartum HPV vaccination program are presented. Overall, their results show an increased rate of immunization (hazard ratio of 2.51) and an increased proportion of women completing the vaccination series (35.8% of those receiving an inpatient dose completed the series compared to 9.3% of those who did not get the inpatient dose).
-
When Is the Ideal Time in the Menstrual Cycle for IUD Insertion?
In this retrospective cohort study, women using the levonorgestrel intrauterine device for noncontraceptive indications had higher expulsion rates (38% vs. 17%, P = 0.03) when insertion occurred on day 1 to day 8 of the menstrual cycle compared to after day 8.